Search clinical trials for: Cemiplimab-Rwlc

Total 255 results

Columbia University
Regeneron Pharmaceuticals

Recruiting

Gemcitabine, Cisplatin, Nab-paclitaxel (GAP) and Cemiplimab for Locally Advanced Biliary Tract Cancer (BTC) (GAP Cemi)

Colon and Rectal Cancer

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Cemiplimab in Treating Patients With Recurrent and Resectable Stage II-IV Head and Neck Cutaneous Squamous Cell Cancer Before Surgery

Stage III Cutaneous Squamous Cell Carcinoma of the Head and Neck AJCC v8 | Stage IV Cutaneous Squamous Cell Carcinoma of the Head and Neck AJCC v8 | Recurrent Cutaneous Squamous Cell Carcinoma of the Head and Neck | Resectable Cutaneous Squamous Cell Carcinoma of the Head and Neck | Stage...

United States
University of Southern California
National Cancer Institute (NCI)

Active, not recruiting

A PD-1 Checkpoint Inhibitor (Cemiplimab) for High-Risk Localized, Locally Recurrent, or Regionally Advanced Skin Cancer

Recurrent Skin Squamous Cell Carcinoma | Resectable Skin Squamous Cell Carcinoma | Stage I Skin Cancer | Stage II Skin Cancer | Stage III Skin Cancer

United States
Georgetown University
Regeneron Pharmaceuticals

Recruiting

Neoadjuvant Chemo-Immunotherapy and Surgical Resection in Locally Advanced Non-small Cell Lung Cancer With N3 Lymph Node or Other High Risk Features (NEO-SURG)

Non-small Cell Lung Cancer Stage III

United States
H. Lee Moffitt Cancer Center and Research Institute
Regeneron Pharmaceuticals; Sanofi-Synthelabo

Recruiting

Neoadjuvant Cemiplimab in Newly Diagnosed or Recurrent Stage I-II Merkel Cell Carcinoma and Locoregionally Advanced Cutaneous Squamous Cell Carcinoma

Merkel Cell Carcinoma | Cutaneous Squamous Cell Carcinoma

United States

Search clinical trials for: Cemiplimab-Rwlc

This is a preview